AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER
Sep 252013
 

File:Zolmitriptan.svg

ZOLMITRIPTAN

 A paper from Emcure

Four isomeric unknown impurities ranging from 0.08-0.12% were found in the purified sample of Zolmitriptan during the batch analysis by gradient reverse phase ultra performance liquid chromatography (UPLC) and their molecular weights determined by liquid chromatography mass spectroscopy (LC-MS) analysis. Subsequently, all the four impurities were isolated by flash chromatography followed by semi-preparative HPLC and characterized by 1H NMR, 13C NMR, 1H-1H COSY, HMBC, HSQC, MS spectroscopy and HPLC. The structures for these four impurities were assigned to be following
Isomeric Impurity-1: 4-((3-(2-(dimethylamino)ethyl)-4-(2-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one,
Isomeric Impurity-2: 4-((3-(2-(dimethylamino)ethyl)-2-(4-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one-,
Isomeric Impurity-3: 4-((3-(2-(dimethylamino)ethyl)-7-(4-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one,
Isomeric Impurity-4: 4-((3-(2-(dimethylamino)ethyl)-6-(4-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one
Isolation and characterization of impurities has helped us in improving the purity of API by removing these impurities using crystallization.

READ ALL THIS AT

http://www.omicsonline.org/isolation-and-structural-elucidation-of-novel-isomeric-process-related-impurities-of-zolmitriptan-2155-9872.1000165.php?aid=13012#

Neelakandan K
API Research Centre
Emcure Pharmaceutical Limited
Hinjawadi, Pune, 411057, India
Fax: +91 20 39821445
E-mail: Neelakandan.K@emcure.co.in

Volume 4, Issue 2
Research Article:  J Anal Bioanal Tech 2013, 4:165
doi: 10.4172/2155-9872.1000165
Isolation and Structural Elucidation of Novel Isomeric Process Related Impurities of Zolmitriptan
Neelakandan K, Chaudhari Ashok, Manikandan H, Santosha N, Prabhakaran B and Mukund Gurjar
Citation: Neelakandan K, Ashok C, Manikandan H, Santosha N, Prabhakaran B, et al. (2013) Isolation and Structural Elucidation of Novel Isomeric Process Related Impurities of Zolmitriptan. J Anal Bioanal Tech 4:165. doi: 10.4172/2155-9872.1000165

………….
Mukund Keshao Gurjar

Dr. Mukund Gurjar is an Executive Director and Chief Scientific Officer (Research and Development) of this Company(Emcure). He is a graduate, a post graduate and Ph.D. in Chemistry from the Nagpur University. He also holds a second Ph. D. degree in Chemistry from the London University, United Kingdom as well as a post doctoral fellowship from Toronto, Canada. Prior to joining our Company, he was the deputy director of the National Chemical Laboratory, Pune where he spent 25 years spearheading innovative and advance research in Organic Chemistry. He has over 32 years of experience in pharmaceutical sciences and is a fellow at various national and international academies. He is a member of the editorial board of the prestigious journal Organic Process Research & Development published by the American Chemical Society. For his contributions to synthetic organic chemistry involving both basic and applied research, he has been felicitated with various awards. A large number of students have obtained Ph.Ds under the supervision of Dr. Gurjar and has published more than 200 papers in various international journals. He has been associated with our Company since 2001 and also became a member of the Board in the same year.

Share

Takeda Gets Simultaneous EU OKs for Three Type 2 Diabetes Therapies

 diabetes  Comments Off on Takeda Gets Simultaneous EU OKs for Three Type 2 Diabetes Therapies
Sep 252013
 

Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, VipidiaTM (alogliptin) and Fixed-Dose Combinations VipdometTM (alogliptin and metformin) and IncresyncTM (alogliptin and pioglitazone)

Osaka, Japan, September 24, 2013 – Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted Marketing Authorization (MA) for VipidiaTM (alogliptin), a dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of type 2 diabetes patients who are uncontrolled on existing therapies1-3and for the fixed-dose combination (FDC) therapies VipdometTM (alogliptin with metformin) and IncresyncTM (alogliptin with pioglitazone). The Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), issued a positive opinion for these products on July 26, 2013.http://www.pharmalive.com/takeda-gets-simultaneous-eu-oks-for-three-new-type-2-diabetes-therapies

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: